News & Updates
Filter by Specialty:
Carotid atherosclerosis ups risk of small fibre nerve dysfunction in T2D
Among patients with type 2 diabetes (T2D), the presence of carotid atherosclerosis appears to aggravate the risk of developing small fibre nerve dysfunction, a recent study has found.
Carotid atherosclerosis ups risk of small fibre nerve dysfunction in T2D
14 Dec 2022
Do supplements measure up to statins for lipid-lowering?
In individuals with increased 10-year risk for ASCVD*, rosuvastatin 5 mg significantly reduced LDL-C** and other lipid and inflammatory biomarkers compared with placebo and six widely used heart health supplements, results from the SPORT*** trial have shown.
Do supplements measure up to statins for lipid-lowering?
13 Dec 2022
Low-dose polypill: Another step forward in hypertension management?
A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.
Low-dose polypill: Another step forward in hypertension management?
12 Dec 2022
CV benefits of dapagliflozin evident regardless of baseline kidney function
The cardiovascular (CV) benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is evident regardless of baseline kidney function, according to an analysis of the DELIVER* trial presented at Kidney Week 2022.
CV benefits of dapagliflozin evident regardless of baseline kidney function
11 Dec 2022
Add-on radiation therapy poses higher cardiovascular risk in stage III NSCLC
The addition of radiation therapy to chemotherapy may be more detrimental than beneficial in patients with resectable stage III nonsmall‐cell lung cancer (NSCLC), being associated with a heightened risk of severe cardiac events, as shown in a study.
Add-on radiation therapy poses higher cardiovascular risk in stage III NSCLC
09 Dec 2022
Diabetes and COVID-19: What have we learned so far?
Evidence for excess risk and increased burden of new-onset diabetes among COVID-19 survivors is robust, and most antihyperglycaemic drugs can be used safely during acute COVID-19, with some drugs potentially offering protection against serious complications, according to data presented at 5th EDM HK.